Vascular tumor targeting.
The growth of solid tumors is dependent on their capacity to acquire blood supply. Therefore, much effort has been directed towards the development of anti-angiogenic agents which inhibit the process of neovascularization. More recently, it has become apparent that the targeted destruction of the established tumor vasculature represents a complementary avenue for growing therapeutic opportunities. This review provides evidence that vascular tumor targeting is an effective anti-tumor strategy in animal models. It further describes strategies for the identification of putative tumor vascular targets and discusses future prospects for vascular targeting applications in the clinical setting.
Ahlskog
J
J
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Paganelli
G
G
Neri
D
D
D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000532:radiotherapy*; D009389:Neovascularization, Pathologic / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D011868:Radioisotopes; D019275:Radiopharmaceuticals